|
June 30, 2019 - 02:55 AM Theodore from Singapore alonso8r@yahoo.com Gloomy tales http://rulertube.fun/ rulertube.com If approved, the vaccine is unlikely to be anything other than neutral for GSK\'s bottom line. GSK has promised that if RTS,S is given the market go-ahead, it will be priced at cost of manufacture plus a 5 percent margin, and the margin would be reinvested in malaria research. |